Filippo Belardelli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3871459/publications.pdf

Version: 2024-02-01

175 papers	13,674 citations	23544 58 h-index	22808 112 g-index
189 all docs	189 docs citations	189 times ranked	15519 citing authors

#	Article	IF	Citations
1	Type I Interferons Potently Enhance Humoral Immunity and Can Promote Isotype Switching by Stimulating Dendritic Cells In Vivo. Immunity, 2001, 14, 461-470.	6.6	865
2	Cancer cellâ€“autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nature Medicine, 2014, 20, 1301-1309.	15.2	823
3	Type I Interferon as a Powerful Adjuvant for Monocyte-Derived Dendritic Cell Development and Activity in Vitro and in Hu-Pbl-Scid Mice. Journal of Experimental Medicine, 2000, 191, 1777-1788.	4.2	590
4	Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood, 2002, 99, 3263-3271.	0.6	446
5	Role of interferons and other cytokines in the regulation of the immune response. Apmis, 1995, 103, 161-179.	0.9	403
6	Effect of Proton Pump Inhibitor Pretreatment on Resistance of Solid Tumors to Cytotoxic Drugs. Journal of the National Cancer Institute, 2004, 96, 1702-1713.	3.0	395
7	IL-15 Is Expressed by Dendritic Cells in Response to Type I IFN, Double-Stranded RNA, or Lipopolysaccharide and Promotes Dendritic Cell Activation. Journal of Immunology, 2001, 167, 1179-1187.	0.4	389
8	ICSBP Is Essential for the Development of Mouse Type I Interferon-producing Cells and for the Generation and Activation of CD8Î±+ Dendritic Cells. Journal of Experimental Medicine, 2002, 196, 1415-1425.	4.2	389
9	Interferon-alpha in tumor immunity and immunotherapy. Cytokine and Growth Factor Reviews, 2002, 13, 119-134.	3.2	306
10	Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis. Cancer Research, 2011, 71, 768-778.	0.4	304
11	The neglected role of type I interferon in the T-cell response: implications for its clinical use. Trends in Immunology, 1996, 17, 369-372.	7.5	271
12	Cytokines as a link between innate and adaptive antitumor immunity. Trends in Immunology, 2002, 23, 201-208.	2.9	271
13	Interferon-Î± and cancer: Mechanisms of action and new perspectives of clinical use. Biochimie, 2007, 89, 884-893.	1.3	243
14	Expression of CCR-7, MIP-3Î², and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood, 2001, 98, 3022-3029.	0.6	231
15	Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration. Clinical Cancer Research, 2007, 13, 644-653.	3.2	228
16	Type I IFN as a Natural Adjuvant for a Protective Immune Response: Lessons from the Influenza Vaccine Model. Journal of Immunology, 2002, 169, 375-383.	0.4	208
17	Reciprocal Activating Interaction Between Dendritic Cells and Pamidronate-Stimulated Î³Î´ T Cells: Role of CD86 and Inflammatory Cytokines. Journal of Immunology, 2005, 174, 252-260.	0.4	208
18	A Contribution of Mouse Dendritic Cellâ€“Derived IL-2 for NK Cell Activation. Journal of Experimental Medicine, 2004, 200, 287-295.	4.2	200

#	Article	IF	Citations
19	Cyclophosphamide induces type I interferon and augments the number of CD44hi T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood, 2000, 95, 2024-2030.	0.6	189
20	European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. Cancer Epidemiology, 2015, 39, S1-S10.	0.8	176
21	Chimeric Plant Virus Particles as Immunogens for Inducing Murine and Human Immune Responses against Human Immunodeficiency Virus Type 1. Journal of Virology, 2001, 75, 8434-8439.	1.5	173
22	Loss of CCR2 Expression and Functional Response to Monocyte Chemotactic Protein (MCP-1) During the Differentiation of Human Monocytes: Role of Secreted MCP-1 in the Regulation of the Chemotactic Response. Blood, 1999, 94, 875-883.	0.6	154
23	IFN-Î³ Expression in Macrophages and Its Possible Biological Significance. Cytokine and Growth Factor Reviews, 1998, 9, 117-123.	3.2	143
24	Suppressive Effect of 1Î±,25-Dihydroxyvitamin D3 on Type I IFN-Mediated Monocyte Differentiation into Dendritic Cells: Impairment of Functional Activities and Chemotaxis. Journal of Immunology, 2005, 174, 270-276.	0.4	140
25	IFN-Î±-conditioned dendritic cells are highly efficient in inducing cross-priming CD8+ T cells against exogenous viral antigens. European Journal of Immunology, 2006, 36, 2046-2060.	1.6	132
26	Potent Immune Response against HIV-1 and Protection from Virus Challenge in hu-PBL-SCID Mice Immunized with Inactivated Virus-pulsed Dendritic Cells Generated in the Presence of IFN-Î±. Journal of Experimental Medicine, 2003, 198, 361-367.	4.2	130
27	Cross talk between cancer and immune cells: exploring complex dynamics in a microfluidic environment. Lab on A Chip, 2013, 13, 229-239.	3.1	126
28	IFN-Î± enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood, 2012, 119, 1407-1417.	0.6	119
29	Inhibition of Angiogenesis and Vascular Tumor Growth by Interferon-Producing Cells. American Journal of Pathology, 2000, 156, 1381-1393.	1.9	117
30	Antiviral effect of bovine lactoferrin saturated with metal ions on early steps of human immunodeficiency virus type 1 infection. International Journal of Biochemistry and Cell Biology, 1998, 30, 1055-1063.	1.2	115
31	Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. Aids, 2003, 17, 1597-1604.	1.0	110
32	Type I IFNs Control Antigen Retention and Survival of CD8Î±+ Dendritic Cells after Uptake of Tumor Apoptotic Cells Leading to Cross-Priming. Journal of Immunology, 2011, 186, 5142-5150.	0.4	110
33	Immunization of Stage IV Melanoma Patients with Melan-A/MART-1 and gp100 Peptides plus IFN-Î± Results in the Activation of Specific CD8+ T Cells and Monocyte/Dendritic Cell Precursors. Cancer Research, 2006, 66, 4943-4951.	0.4	108
34	Role of Cross-Talk between IFN-Î±-Induced Monocyte-Derived Dendritic Cells and NK Cells in Priming CD8+ T Cell Responses against Human Tumor Antigens. Journal of Immunology, 2004, 172, 5363-5370.	0.4	103
35	Chemotherapy enhances vaccineâ€induced antitumor immunity in melanoma patients. International Journal of Cancer, 2009, 124, 130-139.	2.3	103
36	ICSBP is critically involved in the normal development and trafficking of Langerhans cells and dermal dendritic cells. Blood, 2004, 103, 2221-2228.	0.6	98

#	Article	IF	Citations
37	Human Immunodeficiency Virus Type 1 gp120 Induces Abnormal Maturation and Functional Alterations of Dendritic Cells: a Novel Mechanism for AIDS Pathogenesis. Journal of Virology, 2004, 78, 9763-9772.	1.5	95
38	Recent advances on the immunomodulatory effects of IFN-Î±: Implications for cancer immunotherapy and autoimmunity. Autoimmunity, 2010, 43, 204-209.	1.2	92
39	Endogenous type I interferons as a defense against tumors. Cytokine and Growth Factor Reviews, 2002, 13, 111-118.	3.2	90
40	Effect Of Human Natural Killer and Î³Î´ T Cells on the Growth of Human Autologous Melanoma Xenografts in SCID Mice. Cancer Research, 2004, 64, 378-385.	0.4	90
41	Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine, 2005, 23, 2994-3004.	1.7	88
42	Type I Interferons as Regulators of Human Antigen Presenting Cell Functions. Toxins, 2014, 6, 1696-1723.	1.5	83
43	Monocyte-Derived Dendritic Cells Generated After a Short-Term Culture with IFN-Î± and Granulocyte-Macrophage Colony-Stimulating Factor Stimulate a Potent Epstein-Barr Virus-Specific CD8+ T Cell Response. Journal of Immunology, 2003, 170, 5195-5202.	0.4	79
44	The Natural Alliance Between Type I Interferon and Dendritic Cells and Its Role in Linking Innate and Adaptive Immunity. Journal of Interferon and Cytokine Research, 2002, 22, 1071-1080.	0.5	77
45	Type I IFN Protects Permissive Macrophages fromLegionella pneumophilaInfection through an IFN-Î³-Independent Pathway. Journal of Immunology, 2004, 173, 1266-1275.	0.4	77
46	IFN Regulatory Factor-1 Negatively Regulates CD4+CD25+ Regulatory T Cell Differentiation by Repressing Foxp3 Expression. Journal of Immunology, 2008, 181, 1673-1682.	0.4	76
47	Cyclophosphamide Induces a Type I Interferonâ€“Associated Sterile Inflammatory Response Signature in Cancer Patients' Blood Cells: Implications for Cancer Chemoimmunotherapy. Clinical Cancer Research, 2013, 19, 4249-4261.	3.2	73
48	Type I Interferons and Cancer: An Evolving Story Demanding Novel Clinical Applications. Cancers, 2019, 11, 1943.	1.7	73
49	HIV-1 gp120 Stimulates the Production of Î²-Chemokines in Human Peripheral Blood Monocytes Through a CD4-Independent Mechanism. Journal of Immunology, 2001, 166, 5381-5387.	0.4	72
50	APC Activation by IFN-Î± Decreases Regulatory T Cell and Enhances Th Cell Functions. Journal of Immunology, 2010, 184, 5969-5979.	0.4	72
51	Unraveling Cancer Chemoimmunotherapy Mechanisms by Gene and Protein Expression Profiling of Responses to Cyclophosphamide. Cancer Research, 2011, 71, 3528-3539.	0.4	72
52	LOX-1 as a natural IFN-Î±â€“mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells. Blood, 2010, 115, 1554-1563.	0.6	70
53	IFN-Î± promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood, 2004, 103, 980-987.	0.6	68
54	Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Annals of the New York Academy of Sciences, 2010, 1194, 169-178.	1.8	64

#	Article	IF	Citations
55	A Type I IFN-Dependent Pathway Induced by Schistosoma mansoni Eggs in Mouse Myeloid Dendritic Cells Generates an Inflammatory Signature. Journal of Immunology, 2004, 172, 3011-3017.	0.4	63
56	Monocyte/macrophage-derived CC chemokines and their modulation by HIV-1 and cytokines: A complex network of interactions influencing viral replication and AIDS pathogenesis. Journal of Leukocyte Biology, 2003, 74, 719-725.	1.5	62
57	Dual Role of the HIV-1 Vpr Protein in the Modulation of the Apoptotic Response of T Cells. Journal of Immunology, 2000, 165, 3293-3300.	0.4	61
58	Interferon-Î±-Conditioned Human Monocytes Combine a Th1-Orienting Attitude with the Induction of Autologous Th17 Responses: Role of IL-23 and IL-12. PLoS ONE, 2011, 6, e17364.	1.1	60
59	Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications. Seminars in Cancer Biology, 2000, 10, 145-157.	4.3	59
60	Type I Interferon Is a Powerful Inhibitor of in Vivo HIV-1 Infection and Preserves Human CD4+ T Cells from Virus-Induced Depletion in SCID Mice Transplanted with Human Cells. Virology, 1999, 263, 78-88.	1.1	57
61	Role of the cytokine environment and cytokine receptor expression on the generation of functionally distinct dendritic cells from human monocytes. European Journal of Immunology, 2008, 38, 750-762.	1.6	57
62	Dendritic cells and cytokines in immune rejection of cancer. Cytokine and Growth Factor Reviews, 2008, 19, 93-107.	3.2	57
63	Dacarbazine Treatment before Peptide Vaccination Enlarges T-Cell Repertoire Diversity of Melan-Aâ€“Specific, Tumor-Reactive CTL in Melanoma Patients. Cancer Research, 2010, 70, 7084-7092.	0.4	57
64	Endogenous CCL2 (monocyte chemotactic protein-1) modulates human immunodeficiency virus type-1 replication and affects cytoskeleton organization in human monocyteâ€“derived macrophages. Blood, 2003, 102, 2334-2337.	0.6	55
65	Phosphatidylcholine-specific phospholipase C activation is required for CCR5-dependent, NF-kBâ€“driven CCL2 secretion elicited in response to HIV-1 gp120 in human primary macrophages. Blood, 2008, 111, 3355-3363.	0.6	54
66	IFN-alpha in the Generation of Dendritic Cells for Cancer Immunotherapy. Handbook of Experimental Pharmacology, 2009, , 295-317.	0.9	53
67	Inhibition of animal virus production by means of translation inhibitors unable to penetrate normal cells. Virology, 1980, 106, 123-132.	1.1	49
68	Adoptive transfer of an anti-MART-12735-specific CD8+ Tâ€„cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice. European Journal of Immunology, 2003, 33, 556-566.	1.6	48
69	Infection of HHV-8+ primary effusion lymphoma cells with a recombinant Epstein-Barr virus leads to restricted EBV latency, altered phenotype, and increased tumorigenicity without affecting TCL1 expression. Blood, 2004, 103, 313-316.	0.6	48
70	IRF-8 Controls Melanoma Progression by Regulating the Cross Talk between Cancer and Immune Cells within the Tumor Microenvironment. Neoplasia, 2012, 14, 1223-IN43.	2.3	48
71	Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy. Molecular Oncology, 2012, 6, 1-14.	2.1	48
72	A multidisciplinary study usingin vivotumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells. Journal of Immunotoxicology, 2014, 11, 337-346.	0.9	48

#	Article	IF	Citations
73	Type I interferons as vaccine adjuvants against infectious diseases and cancer. Expert Review of Vaccines, 2008, 7, 373-381.	2.0	47
74	Interferon treatment markedly inhibits the development of tumor metastases in the liver and spleen and increases survival time of mice after intravenous inoculation of friend erythroleukemia cells. International Journal of Cancer, 1988, 41, 135-142.	2.3	46
75	Human Immunodeficiency Virus Type 1 gp120 and Other Activation Stimuli Are Highly Effective in Triggering Alpha Interferon and CC Chemokine Production in Circulating Plasmacytoid but Not Myeloid Dendritic Cells. Journal of Virology, 2005, 79, 12597-12601.	1.5	46
76	Role of type I interferon in inducing a protective immune response: Perspectives for clinical applications. Cytokine and Growth Factor Reviews, 2015, 26, 195-201.	3.2	46
77	IFNâ€Î±₁ gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice. International Journal of Cancer, 1995, 60, 221-229.	2.3	44
78	Cure of Mice with Established Metastatic Friend Leukemia Cell Tumors by a Combined Therapy with Tumor Cells Expressing Both Interferon-Î±1 and Herpes Simplex Thymidine Kinase Followed by Ganciclovir. Human Gene Therapy, 1996, 7, 1-10.	1.4	43
79	Human Immunodeficiency Virus Type 1 Strains R5 and X4 Induce Different Pathogenic Effects in hu-PBL-SCID Mice, Depending on the State of Activation/Differentiation of Human Target Cells at the Time of Primary Infection. Journal of Virology, 1999, 73, 6453-6459.	1.5	43
80	IFN-Î± boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity. Immunobiology, 2011, 216, 537-547.	0.8	42
81	Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant friend erythroleukemia cells. VIII. Role of the immune system in the inhibition of visceral metastases. International Journal of Cancer, 1990, 46, 468-474.	2.3	41
82	Vaginal transmission of HIV-1 in hu-SCID mice: a new model for the evaluation of vaginal microbicides. Aids, 2001, 15, 2231-2238.	1.0	41
83	Interferon-Î± as Antiviral and Antitumor Vaccine Adjuvants: Mechanisms of Action and Response Signature. Journal of Interferon and Cytokine Research, 2012, 32, 235-247.	0.5	41
84	Anti-nerve growth factor Ab abrogates macrophage-mediated HIV-1 infection and depletion of CD4+ T lymphocytes in hu-SCID mice. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8927-8932.	3.3	40
85	Recombinant interferon-Î±2b improves immune response to hepatitis B vaccination in haemodialysis patients: Results of a randomised clinical trial. Vaccine, 2009, 27, 5654-5660.	1.7	39
86	Interferon (IFN)-Î² Gene Transfer into TS/A Adenocarcinoma Cells and Comparison with IFN-Î±. American Journal of Pathology, 1999, 154, 1211-1222.	1.9	38
87	Loss of Type I IFN Receptors and Impaired IFN Responsiveness During Terminal Maturation of Monocyte-Derived Human Dendritic Cells. Journal of Immunology, 2002, 169, 3038-3045.	0.4	37
88	Role of endogenous interferon and LPS in the immunomodulatory effects of bovine lactoferrin in murine peritoneal macrophages. Journal of Leukocyte Biology, 2007, 82, 347-353.	1.5	37
89	Antitumor Effect of Thymosin Î±1/Interleukin-2 or Thymosin Î±1/Interferon Î±,Î² Following Cyclophosphamide in Mice Injected with Highly Metastatic Friend Erythroleukemia Cells. Journal of Immunotherapy, 1993, 13, 7-17.	1.2	36
90	Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma. Journal of Translational Medicine, 2015, 13, 139.	1.8	36

#	Article	IF	Citations
91	Epstein-Barr virus infection induces miR-21 in terminally differentiated malignant B cells. International Journal of Cancer, 2015, 137, 1491-1497.	2.3	34
92	Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells. Cancer Immunology Research, 2018, 6, 658-670.	1.6	34
93	Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNÎ±-Dendritic Cells and Rituximab: a Phase I Clinical Trial. Clinical Cancer Research, 2019, 25, 5231-5241.	3.2	34
94	Cytokines as natural adjuvants for vaccines: where are we now?. Trends in Immunology, 2002, 23, 381-383.	2.9	33
95	Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus. Vaccine, 2006, 24, S56-S57.	1.7	33
96	IRF-4 expression in the human myeloid lineage: up-regulation during dendritic cell differentiation and inhibition by 1Î±,25-dihydroxyvitamin D3. Journal of Leukocyte Biology, 2005, 77, 944-947.	1.5	32
97	Role of interferon regulatory factor 1 in governing <scp>T</scp>reg depletion, <scp>T</scp>h1 polarization, inflammasome activation and antitumor efficacy of cyclophosphamide. International Journal of Cancer, 2018, 142, 976-987.	2.3	32
98	Type I IFN regulate DC turnover in vivo. European Journal of Immunology, 2009, 39, 1807-1818.	1.6	31
99	Apicidin and Docetaxel Combination Treatment Drives CTCFL Expression and HMGB1 Release Acting as Potential Antitumor Immune Response Inducers in Metastatic Breast Cancer Cells. Neoplasia, 2012, 14, 855-IN19.	2.3	31
100	IFN-Î± as a vaccine adjuvant: recent insights into the mechanisms and perspectives for its clinical use. Expert Review of Vaccines, 2011, 10, 487-498.	2.0	29
101	The biological relevance of polykaryons in the immune response. Trends in Immunology, 1997, 18, 522-527.	7.5	27
102	Immunomodulatory effects of the HIV-1 gp120 protein on antigen presenting cells: implications for AIDS pathogenesis. Immunobiology, 2004, 209, 99-115.	0.8	27
103	IL-2 induces expression and secretion of IFN-Î³ in murine peritoneal macrophages. Journal of Leukocyte Biology, 2005, 78, 686-695.	1.5	27
104	Antitumor Effects of Epidrug/IFNÎ± Combination Driven by Modulated Gene Signatures in Both Colorectal Cancer and Dendritic Cells. Cancer Immunology Research, 2017, 5, 604-616.	1.6	27
105	Induction of cytokines by HIV-1 and its gp120 protein in human peripheral blood monocyte/macrophages and modulation of cytokine response during differentiation. Journal of Leukocyte Biology, 1997, 62, 49-53.	1.5	26
106	CD2+/CD14+ monocytes rapidly differentiate into CD83+ dendritic cells. European Journal of Immunology, 2003, 33, 358-367.	1.6	26
107	IFN-Î± Regulates Blimp-1 Expression via miR-23a and miR-125b in Both Monocytes-Derived DC and pDC. PLoS ONE, 2013, 8, e72833.	1.1	26
108	Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant friend leukemia cells. IV. Definition of optimal treatment regimens. International Journal of Cancer, 1986, 38, 251-257.	2.3	25

#	Article	IF	Citations
109	ICSBP/IRF-8 differentially regulates antigen uptake during dendritic-cell development and affects antigen presentation to CD4+ T cells. Blood, 2006, 108, 609-617.	0.6	25
110	IFN-Î± potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer. Oncotarget, 2016, 7, 26361-26373.	0.8	25
111	Interaction of IFN Î±/Î² with host cells essential to the early inhibition of friend erythroleukemia visceral metastases in mice. International Journal of Cancer, 1994, 57, 604-611.	2.3	24
112	The essential role of endogenous IFN Î±/Î² in the anti-metastatic action of sensitized T lymphocytes in mice injected with friend erythroleukemia cells. International Journal of Cancer, 1995, 63, 726-731.	2.3	24
113	Murine granulocytes control human tumor growth in SCID mice. International Journal of Cancer, 2000, 87, 569-573.	2.3	24
114	Antitumor activity of recombinant adenoviral vectors expressing murine IFN-Î± in mice injected with metastatic IFN-resistant tumor cells. Cancer Gene Therapy, 2001, 8, 63-72.	2.2	24
115	A good manufacturing practice method to ex vivo expand natural killer cells for clinical use. Blood Transfusion, 2015, 13, 464-71.	0.3	23
116	Type I Interferon Gene Transfer Sensitizes Melanoma Cells to Apoptosis via a Target Activity on Mitochondrial Function. American Journal of Pathology, 2002, 160, 1507-1520.	1.9	22
117	Pertussis toxin B-oligomer inhibits HIV infection and replication in hu-PBL-SCID mice. International Immunology, 2005, 17, 469-475.	1.8	22
118	IFN-Â and Novel Strategies of Combination Therapy for Cancer. Annals of the New York Academy of Sciences, 2007, 1112, 256-268.	1.8	22
119	CC chemokine ligand 2 down-modulation by selected Toll-like receptor agonist combinations contributes to T helper 1 polarization in human dendritic cells. Blood, 2009, 114, 796-806.	0.6	21
120	Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells. Cancers, 2019, 11, 1491.	1.7	20
121	Anti-tumor effects of interferon in mice injected with interferonsensitive and interferon-resistant friend leukemia cells. VI. Adjuvant therapy after surgery in the inhibition of liver and spleen metastases. International Journal of Cancer, 1987, 39, 789-792.	2.3	19
122	Role of endogenous interferon-Î² in the restriction of HIV replication in human monocyte/macrophages. Journal of Leukocyte Biology, 1994, 56, 358-361.	1.5	19
123	U937-SCID mouse xenografts: a new model for acute in vivo HIV-1 infection suitable to test antiviral strategies. Antiviral Research, 1997, 36, 81-90.	1.9	19
124	Evaluation of the effects of human leukocyte IFN-Î± on the immune response to the HBV vaccine in healthy unvaccinated individuals. Vaccine, 2008, 26, 1038-1049.	1.7	19
125	NK Cell Activation in the Antitumor Response Induced by IFN-Î± Dendritic Cells Loaded with Apoptotic Cells from Follicular Lymphoma Patients. Journal of Immunology, 2016, 197, 795-806.	0.4	19
126	Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?. Cytokine and Growth Factor Reviews, 2020, 54, 43-50.	3.2	19

#	Article	IF	Citations
127	Sensitized T lymphocytes render DBA/2 beige mice responsive to IFN Î±/Î² therapy of friend erythroleukemia visceral metastases. International Journal of Cancer, 1993, 54, 475-481.	2.3	18
128	Lenalidomide improves the therapeutic effect of an interferon-Î±-dendritic cell-based lymphoma vaccine. Cancer Immunology, Immunotherapy, 2019, 68, 1791-1804.	2.0	18
129	THE SCID MOUSE REACTION TO HUMAN PERIPHERAL BLOOD MONONUCLEAR LEUKOCYTE ENGRAFTMENT. Transplantation, 1995, 60, 1306-1313.	0.5	18
130	Post-translational up-regulation of the cell surface-associated Î± component of the human type I interferon receptor during differentiation of peripheral blood monocytes: role in the biological response to type I interferon. European Journal of Immunology, 1997, 27, 1075-1081.	1.6	17
131	TREATMENT OF SEVERE COMBINED IMMUNODEFICIENCY MICE WITH ANTI-MURINE GRANULOCYTE MONOCLONAL ANTIBODY IMPROVES HUMAN LEUKOCYTE XENOTRANSPLANTATION1. Transplantation, 1998, 65, 416-420.	0.5	17
132	Inhibition of the Constitutive and Induced IFN-Î² Production by IL-4 and IL-10 in Murine Peritoneal Macrophages. Virology, 2000, 277, 270-277.	1.1	16
133	Concomitant detection of IFNÎ± signature and activated monocyte/dendritic cell precursors in the peripheral blood of IFNÎ±-treated subjects at early times after repeated local cytokine treatments. Journal of Translational Medicine, 2011, 9, 67.	1.8	16
134	Exploiting dendritic cells in the development of cancer vaccines. Expert Review of Vaccines, 2013, 12, 1195-1210.	2.0	15
135	Selective Alteration of the Turnover of Interferon Î² mRNA in Peritoneal Macrophages from LPS-Hyporesponsive Mice and Its Role in the Defective Expression of Spontaneous Interferon. Virology, 1993, 193, 507-509.	1.1	12
136	Type I consensus IFN (IFN-con1) Gene Transfer into KSHV/HHV-8-Infected BCBL-1 Cells Causes Inhibition of Viral Lytic Cycle Activation via Induction of Apoptosis and Abrogates Tumorigenicity in SCID Mice. Journal of Interferon and Cytokine Research, 1999, 19, 1305-1316.	0.5	12
137	Humoral Immune Response and Protection from Viral Infection in Mice Vaccinated with Inactivated MHV-68: Effects of Type I Interferon. Journal of Interferon and Cytokine Research, 2002, 22, 1081-1088.	0.5	12
138	Vaccination with inactivated murine gammaherpesvirus 68 strongly limits viral replication and latency and protects type I IFN receptor knockout mice from a lethal infection. Vaccine, 2004, 22, 1433-1440.	1.7	12
139	Type I Interferons as Regulators of the Differentiation/Activation of Human Dendritic Cells. , 2005, 116, 167-181.		12
140	Opposite regulatory effects of IFN-Î² and IL-3 on C-type lectin receptors, antigen uptake, and phagocytosis in human macrophages. Journal of Leukocyte Biology, 2013, 95, 161-168.	1.5	12
141	Human Lymphoblastoid CD4 ⁺ T Cells Become Permissive to Macrophage-Tropic Strains of Human Immunodeficiency Virus Type 1 after Passage into Severe Combined Immunodeficient Mice through In Vivo Upregulation of CCR5: In Vivo Dynamics of CD4 ⁺ T-Cell Differentiation in Pathogenesis of AIDS. Journal of Virology, 1998, 72, 10323-10327.	1.5	12
142	In situ Vaccination by Direct Dendritic Cell Inoculation: The Coming of Age of an Old Idea?. Frontiers in Immunology, 2019, 10, 2303.	2.2	11
143	Inhibition of lung colonisation of a mouse mammary carcinoma by therapeutic vaccination with interferon-alpha gene-transduced tumor cells. Clinical and Experimental Metastasis, 1998, 16, 123-128.	1.7	10
144	Induction of Both CD8+ and CD4+ T-Cellâ€“Mediated Responses in Colorectal Cancer Patients by Colon Antigen-1. Clinical Cancer Research, 2008, 14, 7292-7303.	3.2	10

#	Article	IF	Citations
145	Efficient Stimulation of T Cell Responses by Human IFN-Î±â€“induced Dendritic Cells Does Not Require Toll-like Receptor Triggering. Journal of Immunotherapy, 2008, 31, 466-474.	1.2	10
146	Inhibitory Activity of Constitutive Nitric Oxide on the Expression of Alpha/Beta Interferon Genes in Murine Peritoneal Macrophages. Journal of Virology, 1999, 73, 7328-7333.	1.5	10
147	Wheat germ agglutinin-binding protein changes in highly malignant Friend leukemia cells metastasizing to the liver. Clinical and Experimental Metastasis, 1988, 6, 347-362.	1.7	9
148	Murine interferon-Î±1 gene-transduced ESb tumor cells are rejected by host-mediated mechanisms despite resistance of the parental tumor to interferon-Î±/Î² therapy. Cancer Gene Therapy, 1999, 6, 246-253.	2.2	9
149	Impairment of Human Immunodeficiency Virus Type 1 (HIV-1) Entry into Jurkat T Cells by Constitutive Expression of the HIV-1 Vpr Protein: Role of CD4 Down-Modulation. Journal of Virology, 2000, 74, 10207-10211.	1.5	9
150	The Italian Hub of Population Biobanks as a Potential Tool for Improving Public Health Stewardship. Biopreservation and Biobanking, 2013, 11, 173-175.	0.5	9
151	Type I Interferons as Joint Regulators of Tumor Growth and Obesity. Cancers, 2021, 13, 196.	1.7	9
152	Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for NaÃ¯ve/Memory T Cell Immunomonitoring. Journal of Immunology Research, 2020, 2020, 1-15.	0.9	8
153	The European Research Infrastructures of the ESFRI Roadmap in Biological and Medical Sciences: status and perspectives. Annali Dell'Istituto Superiore Di Sanita, 2014, 50, 178-85.	0.2	8
154	Importance of interferon Î± in the resistance of allogeneic C57B1/6 mice to the multiplication of friend erythroleukemia cells in the liver. International Journal of Cancer, 1990, 45, 364-371.	2.3	7
155	Training and Mobility: A Priority for the Organisation of the European Cancer Institutes. How a National Mobility Initiative Could Enhance EU Cooperation in Cancer Research Contributing to the Development of an European Research Area: The Example of the Italian Comprehensive Cancer Centersâ€™ Network â€œAlleanza Contro il Cancroâ€• Tumori, 2008, 94, 147-153.	0.6	7
156	Exploiting natural antiviral immunity for the control of pandemics: Lessons from Covid-19. Cytokine and Growth Factor Reviews, 2022, 63, 23-33.	3.2	7
157	Activation of Glycerophosphocholine Phosphodiesterase in Friend Leukemia Cells Upon Inâ€Vitro Induced Erythroid Differentiation. ³¹P and ¹H NMR Studies. Israel Journal of Chemistry, 1992, 32, 291-298.	1.0	6
158	Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study. Frontiers in Oncology, 2020, 10, 202.	1.3	6
159	Type I interferons induce peripheral T regulatory cell differentiation under tolerogenic conditions. International Immunology, 2021, 33, 59-77.	1.8	6
160	Interferon Regulatory Factor 8-Deficiency Determines Massive Neutrophil Recruitment but T Cell Defect in Fast Growing Granulomas during Tuberculosis. PLoS ONE, 2013, 8, e62751.	1.1	6
161	MHV-68 producing mIFNÎ±1 is severely attenuated in vivo and effectively protects mice against challenge with wt MHV-68. Vaccine, 2011, 29, 3935-3944.	1.7	5
162	Differentiation of monocyte-derived dendritic cells is associated with upregulation and activation of Rac-1 small GTPase. FEBS Letters, 2006, 580, 3335-3339.	1.3	4

#	Article	IF	Citations
163	Anticancer Effects of Sublingual Type I IFN in Combination with Chemotherapy in Implantable and Spontaneous Tumor Models. Cells, 2021, 10, 845.	1.8	4
164	Chemo-immunotherapy induces tumor regression in a mouse model of spontaneous mammary carcinogenesis. Oncotarget, 2016, 7, 59754-59765.	0.8	4
165	Role of Cytokines in GVL (ESb Lymphoma) and GVHD After Adoptive Transfer of Allogeneic T Lymphocytes in Mice. Journal of Interferon and Cytokine Research, 1998, 18, 667-679.	0.5	3
166	Accreditation for excellence of cancer research institutes: recommendations from the Italian Network of Comprehensive Cancer Centers. Tumori, 2013, 99, 293e-8e.	0.6	3
167	Correlation between the sensitivity or resistance to IL-2 and the response to cyclophosphamide of 4 tumors transplantable in the same murine host. International Journal of Cancer, 1995, 62, 184-190.	2.3	2
168	Cytokines, dendritic cells and immunological rejection. Cytokine and Growth Factor Reviews, 2008, 19, 1-2.	3.2	2
169	Biotherapy of Cancer: Break the Barriers to Foster Translation oF knowledge. Tumori, 2008, 94, 182-188.	0.6	2
170	TRAIN: Training through Research Application Italian Initiative. International Journal of Biological Markers, 2011, 26, 136-138.	0.7	2
171	International Accreditation of Cancer Centres of Italian Network of Alleanza Contro il Cancro: Introductory Remarks. Tumori, 2015, 101, S1-S1.	0.6	2
172	Development of a Pilot Project on Data Sharing among Partners of the Italian Hub of Population Biobanks (HIBP): Association between Lipid Profile and Socio-Demographic Variables. Biopreservation and Biobanking, 2014, 12, 225-233.	0.5	1
173	Application of OECI Accreditation Program to Cancer Institutes of the Alleanza Contro il Cancro Italian Network: A Special Project Supported by the Italian Ministry of Health. Tumori, 2015, 101, S2-S5.	0.6	0
174	Dendritic cells as targets and tools in vaccines. , 2006, , 17-33.		0
175	Adjuvants, Dendritic Cells, and Cytokines: Strategies for Enhancing Vaccine Efficacy. , 2007, , 171-202.		0